IP Library › Granted Patent US 12,310,973
Granted Patent B2
US 12,310,973 · App. 18/131,570 · Granted May 27, 2025

Administration and dosage of diaminophenothiazines

Inventors: Claude Michel Wischik (Aberdeen, GB); Björn Olaf Schelter (Aberdeen, GB); Damon Jude Wischik (Cambridge, GB); John Mervyn David Storey (Aberdeen, GB)
Assignee: WisTa Laboratories Ltd.
A61K31/5415A23L33/105A23L33/12A23L33/15A23P10/28A23P10/30A61K45/06A61P25/28B65D75/36A23V2002/00B65D2203/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,973
App. No.
18/131,570
Granted
May 27, 2025
Kind
B2
Abstract

The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of a acetylcholinesterase levels.

Claims (54)

1. A method of therapeutic treatment of a disorder of protein aggregation which is mild cognitive impairment or Alzheimer's disease in a subject,

which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,

wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day, wherein the MT-containing compound is characterized by a purity of greater than 97% and wherein the MT-containing compound is methylthioninium chloride (MTC), or a hydrate thereof.

2. The method as claimed in claim 1 wherein said therapeutic treatment with the MT-containing compound comprises a total daily dose of MT from any of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 mg to 5, or 6 mg.

3. The method as claimed in claim 1 wherein said therapeutic treatment with the MT-containing compound comprises a total daily dose of MT of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, or 6 mg.

4. The method as claimed in claim 1 wherein said therapeutic treatment comprises a total daily dose of the MT-containing compound administered as a split dose twice a day or three times a day.

5. The method as claimed in claim 1 wherein the MT-containing compound is MTC pentahydrate.

6. The method as claimed in claim 1 wherein the MT-containing compound is characterized by a purity of greater than 98%.

7. The method as claimed in claim 1 , wherein the MT-containing compound is characterized by a purity of greater than 98% and one or more of the following:

(i) less than 1% Azure B as impurity;

(ii) less than 0.13% MVB (Methylene Violet Bernstein) as impurity;

(iii) less than 0.15% Azure A as impurity;

(iv) less than 0.15% Azure C as impurity; or

(v) an elementals purity better than less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

8. The method as claimed in claim 1 , wherein the MT-containing compound is characterized by a purity of greater than 98% and less than 1% Azure B as impurity.

9. The method as claimed in claim 1 , wherein the MT-containing compound is characterized by a purity of greater than 98% and an elementals purity better than less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

10. The method as claimed in claim 1 , wherein the MT-containing compound is characterized by:

(i) at least 98% purity;

(ii) less than 1% Azure B as impurity; and

(iii) an elementals purity better than the European Pharmacopeia limits of less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

11. A method of prophylactic treatment of a disorder of protein aggregation which is mild cognitive impairment or Alzheimer's disease in a subject,

which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,

wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day, wherein the MT-containing compound is characterized by a purity of greater than 97% and wherein the MT-containing compound is methylthioinium chloride (MTC), or a hydrate thereof.

12. The method as claimed in claim 11 wherein the subject has not historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.

13. The method as claimed in claim 11 wherein the disorder is mild cognitive impairment.

14. The method as claimed in claim 11 wherein the disorder is Alzheimer's disease.

15. The method as claimed in claim 11 , wherein the MT-containing compound is administered in the form of a dosage unit,

wherein the amount of MT in the dosage unit is 4 mg.

16. The method as claimed in claim 1 wherein the subject has not historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.

17. The method as claimed in claim 1 wherein said therapeutic treatment comprises a total daily dose of the MT-containing compound administered as a single dose.

18. The method as claimed in claim 5 wherein said therapeutic treatment comprises a total daily dose of MTC pentahydrate of 5 to 10 mg/day.

19. The method as claimed in claim 1 wherein the disorder is mild cognitive impairment.

20. The method as claimed in claim 1 wherein the disorder is Alzheimer's disease.

21. The method as claimed in claim 1 , wherein the MT-containing compound is administered in the form of a dosage unit,

wherein the amount of MT in the dosage unit is 4 mg.

22. The method as claimed in claim 11 wherein said prophylactic treatment with the MT-containing compound comprises a total daily dose of MT from any of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 mg to 5, or 6 mg.

23. The method as claimed in claim 22 wherein said prophylactic treatment with the MT-containing compound comprises a total daily dose of MT of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, or 6 mg.

24. The method as claimed in claim 11 wherein said prophylactic treatment comprises a total daily dose of the MT-containing compound administered as a split dose twice a day or three times a day.

25. The method as claimed in claim 11 wherein said prophylactic treatment comprises a total daily dose of the MT-containing compound administered as a single dose.

26. The method as claimed in claim 11 wherein the MT-containing compound is MTC pentahydrate.

27. The method as claimed in claim 26 wherein said prophylactic treatment comprises a total daily dose of MTC pentahydrate of 5 to 10 mg/day.

28. The method as claimed in claim 11 wherein the MT-containing compound is characterized by a purity of greater than 98%.

29. The method as claimed in claim 11 , wherein the MT-containing compound is characterized by a purity of greater than 98% and one or more of the following:

(i) less than 1% Azure B as impurity;

(ii) less than 0.13% MVB (Methylene Violet Bernstein) as impurity;

(iii) less than 0.15% Azure A as impurity;

(iv) less than 0.15% Azure C as impurity; or

(v) an elementals purity better than less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

30. The method as claimed in claim 11 , wherein the MT-containing compound is characterized by a purity of greater than 98% and less than 1% Azure B as impurity.

31. The method as claimed in claim 11 , wherein the MT-containing compound is characterized by a purity of greater than 98% and an elementals purity better than less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

32. The method as claimed in claim 11 , wherein the MT-containing compound is characterized by:

(i) at least 98% purity;

(ii) less than 1% Azure B as impurity; and

(iii) an elementals purity better than the European Pharmacopeia limits of less than 100 μg/g Aluminium (Al); less than 1 μg/g Cadmium (Cd); less than 100 μg/g Chromium (Cr); less than 300 μg/g Copper (Cu); less than 10 μg/g Tin (Sn); less than 200 μg/g Iron (Fe); less than 10 μg/g Manganese (Mn); less than 1 μg/g Mercury (Hg); less than 10 μg/g Molybdenum (Mo); less than 10 μg/g Nickel (Ni); less than 10 μg/g Lead (Pb); and less than 100 μg/g Zinc (Zn).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2025
From: WISCHIK, CLAUDE MICHEL; SCHELTER, BJÖRN OLAF; STOREY, JOHN MERVYN DAVID
To: WISTA LABORATORIES LTD.
Reel/Frame 069992/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: WISCHIK, DAMON JUDE
To: WISTA LABORATORIES LTD.
Reel/Frame 068427/0303 →
Priority Claims (2)
GB 1612863 · Jul 25, 2016 · national
GB 1710382 · Jun 29, 2017 · national
Continuity (4)
Continuation 17961765 · Oct 7, 2022
Continuation 17349427 · Jun 16, 2021
Continuation 16320148
Related Publication 20230346794A1 · Nov 2, 2023
References Cited (143)
US 9283230B2 · Clunas et al. · 2016 [cited by applicant]
US 10842796B2 · Wischik et al. · 2020 [cited by applicant]
US 11065256B2 · Wischik · 2021 [cited by examiner]
US 11759469B2 · Wischik · 2023 [cited by examiner]
US 12128051B2 · Wischik · 2024 [cited by examiner]
US 20130184268A1 · Pahnke · 2013 [cited by applicant]
US 20190192530A1 · Wischik et al. · 2019 [cited by applicant]
US 20200016165A1 · Wischik et al. · 2020 [cited by applicant]
US 20210236509A1 · Schelter et al. · 2021 [cited by applicant]
US 20220008431A1 · Wischik et al. · 2022 [cited by applicant]
US 20230031369A1 · Riedel et al. · 2023 [cited by applicant]
US 20230115931A1 · Schelter et al. · 2023 [cited by applicant]
US 20230165877A1 · Wischik et al. · 2023 [cited by applicant]
WO WO9630766A1 · 1996 [cited by applicant]
WO WO02055720A2 · 2002 [cited by applicant]
WO WO2002059150A2 · 2002 [cited by applicant]
WO WO2002075318A2 · 2002 [cited by applicant]
WO WO2003101458A1 · 2003 [cited by applicant]
WO WO2006032879A2 · 2006 [cited by applicant]
WO WO2007110627A2 · 2007 [cited by applicant]
WO WO2007110629A1 · 2007 [cited by applicant]
WO WO2007110630A1 · 2007 [cited by applicant]
WO WO2008006979A2 · 2008 [cited by applicant]
WO WO2008007074A2 · 2008 [cited by applicant]
WO WO2008155533A2 · 2008 [cited by applicant]
WO WO2009044127A1 · 2009 [cited by applicant]
WO WO2009060191A2 · 2009 [cited by applicant]
WO WO2010078659A1 · 2010 [cited by applicant]
WO WO2010104394A1 · 2010 [cited by applicant]
WO WO2011036558A2 · 2011 [cited by applicant]
WO WO2011036561A2 · 2011 [cited by applicant]
WO WO2012072977A2 · 2012 [cited by applicant]
WO WO2012107706A1 · 2012 [cited by applicant]
WO WO2018019823A1 · 2018 [cited by applicant]
WO WO2018041739A1 · 2018 [cited by applicant]
WO WO2020020751A1 · 2020 [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2017/068749, mailed May 10, 2017. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2017/068749, mailed Feb. 7, 2019. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2017/071437, mailed Nov. 24, 2017. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2017/071437, mailed Mar. 14, 2019. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2019/069428, mailed Nov. 7, 2019. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2019/069428, mailed Feb. 4, 2021. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/068422, mailed Sep. 28, 2020. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2020/068422, mailed Jan. 13, 2022. [cited by applicant]
Alda et al., Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry. Jan. 2017;210(1):54-60. doi: 10.1192/bjp.bp.115.173930. Epub Jun. 9, 2016. [cited by applicant]
Al-Hilaly et al., Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT). J Mol Biol. Oct. 19, 2018;430(21):4119-4131. doi: 10.1016/j.jmb.2018.08.010… [cited by applicant]
Atamna et al., Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction. Biofactors. Mar.-Apr. 2012;38(2):158-66. doi: 10.1002/biof.197. Epub Mar. 15, 2012. [cited by applicant]
Auchter et al., Methylene Blue Preserves Cytochrome Oxidase Activity and Prevents Neurodegeneration and Memory Impairment in Rats With Chronic Cerebral Hypoperfusion.Front Cell Neurosci. May 20, 2020;14:130. doi: 10.338… [cited by applicant]
Baddeley et al., Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther. Jan. 2015;352(1):110-8. doi: 10.1124/jpet.114.… [cited by applicant]
Bruchey et al., Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. Am J Pharmacol Toxicol. Jan. 1, 2008;3(1):72-79. doi: 10.3844/ajptsp.2008.72.79. [cited by applicant]
Congdon et al., Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. Jul. 2018;14(7):399-415. doi: 10.1038/s41582-018-0013-z. [cited by applicant]
Douaud et al., Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. Jun. 4, 2013;110(23):9523-8. doi: 10.1073/pnas.1301816110. Epub May 20, 2013. [cited by applicant]
Feldman et al., A phase 3 trial of the tau and TDP-43 aggregation inhibitor, leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), for behavioural variant frontotemporal dementia (bvFTD). J Neurochemistry. Jul. 18,… [cited by applicant]
Gauthier et al., Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. Dec. 10, 2016… [cited by applicant]
Gonzalez-Lima et al., Protection against neurodegeneration with low-dose methylene blue and near-infrared light. Front Cell Neurosci. May 12, 2015;9:179. doi: 10.3389/fncel.2015.00179. eCollection 2015. [cited by applicant]
Harrington et al., Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer's disease. J Biol Chem. Apr. 24, 2015;290(17):10862-75. doi… [cited by applicant]
Jaber et al., Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies. Mol Neurobiol. Dec. 2019;56(12):8101-8108. doi: 10.1007/s12035-019-1632-0. Epub Jun. 10, 2019. [cited by applicant]
Kazim et al., Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer's Disease. Chapter 2 in: Neuroprotection in Alzheimer's Disease. 2017; 3-29. https://doi.org/10.1016/B978-0-12-803690-7.00002-8. [cited by applicant]
McGleenon et al., Acetylcholinesterase inhibitors in Alzheimer's disease. Br J Clin Pharmacol. 1999;48(4):471-480. doi: 10.1046/j.1365-2125.1999.00026.x. [cited by applicant]
Mecocci et al., Nutraceuticals in cognitive impairment and Alzheimer's disease. Front Pharmacol. Jun. 23, 2014;5:147. doi: 10.3389/fphar.2014.00147. eCollection 2014. [cited by applicant]
Melis et al., Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. Cell Mol Life Sci. Jun.… [cited by applicant]
Melis et al., Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. Jun. 2015;26(4):353-68. doi: 10.1097/FBP.0000000000000133. [cited by applicant]
Naylor et al., A Controlled Trial of Methylene Blue in Severe Depressive Illness. Biol Psychiatry. May 1987;22(5):657-9. doi: 10.1016/0006-3223(87)90194-6. [cited by applicant]
Oz et al., Methylene blue and Alzheimer's disease. Biochem Pharmacol. Oct. 15, 2009;78(8):927-32. doi: 10.1016/j.bcp.2009.04.034. Epub May 9, 2009. [cited by applicant]
Panza et al., A critical appraisal of amyloid- B-targeting therapies for Alzheimer disease. Nat Rev Neurol. Feb. 2019;15(2):73-88. doi: 10.1038/s41582-018-0116-6. [cited by applicant]
Panza et al., Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub Jun. 26, 2016. [cited by applicant]
Pappas, Statistical Analysis Plan (Addendum)—Randomized Double-Blind, Placebo-Controlled, Parallel-Griup, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alz… [cited by applicant]
Pappas, Statistical Analysis Plan—Randomized Double-Blind, Placebo-Controlled, Parallel-Griup, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer's Di… [cited by applicant]
Rodriguez et al., Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. Nov. 2016;281(2):516-526. doi: 10.1148/radiol.2016152893. Epub Jun. 28, 2016. [cited by applicant]
Schelter et al., Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. J Alzheimers Dis. 2019;72(3):931-946. doi: 10.3233/JAD-190772. [cited by applicant]
Schelter et al., Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer's disease with low dose hydromethylthionine. JPAD. 2018; 5(1):S66. [cited by applicant]
Schirmer et al., “Lest we forget you—methylene blue . . .”. Neurobiol Aging. Dec. 2011;32(12):2325.e7-16. doi: 10.1016/j.neurobiolaging.2010.12.012. Epub Feb. 12, 2011. [cited by applicant]
Shiells et al., Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. J Alzheimers Dis. 2020;75(2):… [cited by applicant]
Smith, B vitamins can slow the disease process in early Alzheimer's disease. University of Oxford Impact case study (REF3b). Research Excellence Framework. 2014. 4 pages. [cited by applicant]
Stack et al., Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. Jul. 15, 2014;23(14):3716-32. doi: 10.1093/hmg/ddu080. Epub Feb. 20, 2014. [cited by applicant]
Telch et al., Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. Oct. 2014;171(10):1091-8. doi: 10.1176/appi.ajp.2014.131014… [cited by applicant]
Tsai et al., Therapy and clinical trials in frontotemporal dementia:past, present, and future. J Neurochem. Aug. 2016;138 Suppl 1:211-21. doi:10.1111/jnc.13640. Epub Jun. 15, 2016. [cited by applicant]
Tsai et al., Treatment of frontotemporal dementia. Curr Treat Options Neurol. Nov. 2014;16(11):319. doi: 10.1007/s11940-014-0319-0. [cited by applicant]
Ustyugo et al., New Therapeutic Property of Dimebon as a Neuroprotective Agent. Curr Med Chem. 2018;25(39):5315-5326. doi: 10.2174/0929867323666160804122746. [cited by applicant]
Wilcock et al., Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical … [cited by applicant]
Wilkinson, Alzheimer'z drug ‘halts’ decline. BBC News Jul. 29, 2008. Accessed at http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7525115.stm on Sep. 21, 2017. [cited by applicant]
Wischik et al., Modeling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development. J Alzheimers Dis. 2018;62(3):1287-1303. doi: 10.3233/JAD-170727. [cited by applicant]
Wischik et al., Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. Jul. 1988;85(13):4884-8. doi: 10.1073/pnas.85.13.4884. [cited by applicant]
Yamashita et al., Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. Jul. 21, 2009;583(14):2419-24. doi:10.1016/j.febslet.2009.06.042. Epub Jun. 26, 2009. [cited by applicant]
Zhao et al., Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation. Mol Med Rep. Jan. 2016;13(1):13-20. doi: 10.3892/mmr.2015.4551. Epu… [cited by applicant]
Albert et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's dise… [cited by applicant]
Arai et al., Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. Apr. 2010;30(2):170-81. doi: 10.1111/j.1440-1789.2009.010… [cited by applicant]
Benedetti et al., Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. Jun. 2016;15(7):736-747. doi: 10.1016/S1474-4422(16)00066-1. Epub Apr. 19, 2016. [cited by applicant]
Boxer et al., The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. Mar. 2013;9(2):189-98. doi: 10.1016/j.jalz.2012.03.… [cited by applicant]
Callaway et al., Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. Jan. 2004;77(1):175-81. doi: 10.1016/j.pbb.2003.10.007. [cited by applicant]
Callaway et al., Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci Lett. Oct. 31, 2002;332(2):83-6. doi: 10.1016/s0304-3940(02)00827-3. [cited by applicant]
Casey et al., Drugs for Alzheimer's disease: are they effective? P T. Apr. 2010;35(4):208-11. [cited by applicant]
Cummings et al., The “rights” of precision drug development for Alzheimer's disease. Alzheimers Res Ther. Aug. 31, 2019;11(1):76. doi: 10.1186/s13195-019-0529-5. [cited by applicant]
Deiana et al., Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl). Jan. 2009;202(1-3):53-65. doi: 10.1007/s00213-008-1394-2. Epub Nov. 1… [cited by applicant]
Desmarais et al., Therapeutic trial design for frontotemporal dementia and related disorders. J Neurol Neurosurg Psychiatry. Apr. 2019;90(4):412-423. doi: 10.1136/jnnp-2018-318603. Epub Oct. 25, 2018. [cited by applicant]
Disanto et al., Pharmacokinetics of highly ionized drugs. II. Methylene blue—absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. Jul. 1972;61(7):1086-90. doi: 10.1002/jps.2600610… [cited by applicant]
Disanto et al., Pharmacokinetics of highly ionized drugs. III. Methylene blue—blood levels in the dog and tissue levels in the rat following intravenous administration. J Pharm Sci. Jul. 1972;61(7):1090-4. doi: 10.1002/… [cited by applicant]
Dolder et al., Use of psychostimulants in patients with dementia. Ann Pharmacother. Oct. 2010;44(10):1624-32. doi: 10.1345/aph.1P341. Epub Aug. 24, 2010. [cited by applicant]
Doody et al., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. Jan. 23, 2014;370(4):311-21. doi: 10.1056/NEJMoa1312889. [cited by applicant]
Franzen et al., Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. Alzheimers Dement. Apr. 2022;18(4):810-823. doi: 10.1002/alz.12433. Epub Sep. 30, 2021. [cited by applicant]
Gonzalez-Lima et al., Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. Sep.-Oct. 2004;11(5):633-40. doi: 10.1101/lm.82404. [cited by applicant]
Huang et al., Alzheimer mechanisms and therapeutic strategies. Cell. Mar. 16, 2012;148(6):1204-22. doi: 10.1016/j.cell.2012.02.040. [cited by applicant]
Irwin, Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. Jan. 2016;22 Suppl 1(01):S29-33. doi: 10.1016/j.parkreldis.2015.09.020. Epub Sep. 8, 2015. [cited by applicant]
Jinwal et al., Chemical manipulation of Hsp70 ATPase activity regulates tau stability. J Neurosci. Sep. 30, 2009;29(39):12079-88. doi: 10.1523/JNEUROSCI.3345-09.2009. [cited by applicant]
Jutten et al., The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimers Dement (N Y). Apr. 17, 2020;6(1):e12020. doi: 1… [cited by applicant]
Jutten et al., Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimers Dement. Feb. 2023;19(2):7… [cited by applicant]
Kertesz, Behavioral and Psychological Symptoms and Frontotemporal Dementia (Pick's Disease). International Psychogeriatrics. 2000; 12(1): 183-187. [cited by applicant]
Kim et al., Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments. Alzheimers Res Ther. Jan. 22, 2019;11(1):10. doi: 10.1186/s13195-018-0462-z. [cited by applicant]
Kumar, Potential medicinal plants for CNS disorders: an overview. Phytother Res. Dec. 2006;20(12):1023-35. doi: 10.1002/ptr.1970. [cited by applicant]
Martinez et al., Methylene blue alters retention of inhibitory avoidance responses. Physiological Psychology. 1978; 6(3): 387-390. [cited by applicant]
May et al., Reduction and uptake of methylene blue by human erythrocytes. Am J Physiol Cell Physiol. Jun. 2004;286(6):C1390-8. doi: 10.1152/ajpcell.00512.2003. Epub Feb. 18, 2004. [cited by applicant]
Mohamed et al., Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem Neurosci. Author manuscript; available in PMC… [cited by applicant]
Moody et al., Methylene blue excretion in depression. Biol Psychiatry. Dec. 1989;26(8):850-2. doi: 10.1016/0006-3223(89)90128-5. [cited by applicant]
Naylor et al., A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry. Aug. 1986;21(10):915-20. doi: 10.1016/0006-3223(86)90265-9. [cited by applicant]
No Author Listed, Clinical Trial ID NCT01689246. Safety and Efficacy Study Evaluating TRx0237 in Subjects with Mild to Moderate Alzheimer's Disease. Submitted: Sep. 20, 2012. Last updated: Mar. 14, 2018. Accessed at: ht… [cited by applicant]
No Author Listed, EudraCT No. 2012-002866-11. Clinical Trial Results: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mi… [cited by applicant]
No Author Listed, TauRx Pharmaceuticals Press Release. Sep. 4, 2016. 3 pages. [cited by applicant]
Panza et al., Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. Apr. 2020;16(4):213-228. doi: 10.1038/s41582-020-0330-x. Epub Mar. 23, 2020. [cited by applicant]
Peter et al., Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. Jun. 2000;56(3):247-50. doi: 10.1007/s002280000124. [cited by applicant]
Pfaffendorf et al., The interaction between methylene blue and the cholinergic system. Br J Pharmacol. Sep. 1997;122(1):95-8. doi: 10.1038/sj.bjp.0701355. [cited by applicant]
Ramsay et al., Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. Nov. 2007;152(6):946-51. doi: 10.1038/sj.bjp.0707430. Epub Aug. 27, 2007. [cited by applicant]
Riha et al., Memory facilitation by methylene blue: Dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. Mar. 28, 2005;511(2-3):151-8. doi: 10.1016/j.ejphar.2005.02.001. [cited by applicant]
Salloway et al., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med. Jan. 23, 2014;370(4):322-33. doi: 10.1056/NEJMoa1304839. [cited by applicant]
Schneider et al., Current Alzheimer's disease clinical trials: Methods and placebo outcomes. Alzheimers Dement. Sep. 2009;5(5):388-97. doi: 10.1016/j.jalz.2009.07.038. [cited by applicant]
Shearman et al., Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study. Brain Res Bull. Mar. 31, 2006;69(2):204-13. Doi: 10.1016/j.brainres… [cited by applicant]
Snyder et al., Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? Alzheimers Dement. Nov. 2014; 10(6):853-60. doi: 10.1016/j.jalz.2014.07.158. Epub Nov. 15, 2014. [cited by applicant]
Sperling et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. A… [cited by applicant]
Tariot et al., The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the… [cited by applicant]
Ustyugov et al., New therapeutic property of Dimebon as a neuroprotective agent. Curr Med Chem. 2018;25(39):5315-5326. doi: 10.2174/0929867323666160804122746. [cited by applicant]
Van Bebber et al., Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis. Sep. 2010;39(3):265-71. doi: 10.1016/j.nbd.2010.03.023. Epub Apr. 8, 2010. [cited by applicant]
Venneri et al., Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport. Jan. 21, 2002;13(1):83-7. doi: 10.1097/00001756-200201210-00020. [cited by applicant]
Vercelletto et al., Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results. J Alzheimers Dis. 2011;23(4):749-59. doi: 10.3233/JAD-2010-101632. [cited by applicant]
Vos et al., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. May 2015;138(Pt 5): 1327-38. doi: 10.1093/brain/awv029. Epub Feb. 17, 2015. [cited by applicant]
Weintraub et al., Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimers Dement (N Y). Feb. 13, 2018:4:64-75. doi: 10.1016/j.trci.2018.01.003. eCollection 2018. [cited by applicant]
Wilcock et al., Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase 3 clinical tr… [cited by applicant]
Wischik et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc Natl Acad Sci USA. Jun. 1988;85(12):4506-10. doi: 10.1073/pnas.85.12.4506. [cited by applicant]
Wischik et al., Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. Neurobiol Aging. May-Jun. 19… [cited by applicant]
Wischik et al., Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. Chapter 11 in: Emerging drugs and targets for Alzheimer's disease: vol. 1: Beta-amyloid, tau protein and gluc… [cited by applicant]
Wischik et al., Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. Oct. 1, 1996;93(20):11213-8. doi: 10.1073/pnas.93.20.11213. [cited by applicant]
Wischik et al., Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis. 2015;44(2):705-20. doi: 10.3233/JAD-142874. [cited by applicant]
Wischik et al., Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol. Apr. 15, 2014;88(4):529-39. doi: 10.1016/j.bcp.2013.12.008. Epub Dec. 19, 2013. [cited by applicant]
Wrubel et al., Methylene blue facilitates the extinction of fear in an animal model of susceptibility to learned helplessness. Neurobiol. Neurobiol Learn Mem. Feb. 2007;87(2):209-17. doi: 10.1016/j.nlm.2006.08.009. Epub… [cited by applicant]
Zoellner et al., Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: a randomized controlled trial. J Clin Psychiatry. Jul. 2017;78(7):e782-e789. doi: 10… [cited by applicant]